IntelliPharmaCeutics International, Inc.

IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS). Its products include Focalin XR, Keppra XR, Effexor XR, Protonix, Seroquel XR, Lamictal XR, Pristiq, Oleptro, Coreg CR, OxyContin and Lyrica.

  

News

IntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) Abuse Deterrent Technology featured at Healthcare Conference

🕔2/18/2017 4:26:00 AM 2193

(NetworkNewsWire) The '2017 Disruptive Growth & Healthcare Conference', which ran February 15-16 at the Convene at 730 Third Avenue Conference Center in midtown Manhattan, New York, featured some stellar participants, either as presenters or as sponsors. Along with over 60 other firms in a variety of fields related to biotech, IntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) (TSE:I) was on the bill.

Read Full Article
###

609 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 18) (Since Published: 609) 

Markets NASDAQ:IPCI

Company Data

Social Media